Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Anglonordic Life Science Conference XXI

The 21st Annual Anglonordic Life Science Conference in London will bring together over 400 delegates from leading drug discovery companies, investment firms, and emerging life [...]

Go to Top